1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva
Executive Summary
Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.
You may also be interested in...
Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
The latest drug development news and highlights from our FDA Performance Tracker.